Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)

PITTSBURGH–(BUSINESS WIRE)–Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections (PJI) on Monday, February 27, 2023 at 11 AM ET.

The panel discussion moderated by Robin R. Young (Founder & CEO, RRY; Publisher of Orthopedics This Week) will feature Ken Urish, MD, PhD (Associate Professor, University of Pittsburgh Department of Orthopaedic Surgery) and Roshawn Blunt (Health Economist; President, Corsaire Corporation). PJI is the leading cause of failures in total joint arthroplasty and is associated with high morbidity, 5-year mortality of over 20% and the need for complex interdisciplinary treatment strategies. Current standards of care include multiple major surgeries with no curative therapeutic solution, leaving a significant impact on patients’ quality of life. Each surgical treatment of PJI leads to direct hospital costs of over $100,000, adding up close to $500,000 in overall costs per patient to treat PJI. The event will feature a patient’s perspective on the physical and mental burden of PJI and will bring together these expert panelists to discuss the clinical and economic burden on the patients and the overall healthcare system.

A live Q&A session will follow the formal presentations. To register for the event, please click here.

Ken Urish, MD, PhD, is an Associate Professor at the University of Pittsburgh departments of Orthopaedic Surgery and Engineering, and an Associate Medical Director at the Bone and Joint Center at UPMC Magee-Womens Hospital. His practice focuses on primary and revision knee and hip replacement. As a physician scientist, Dr. Urish has extensive experience with clinical and translational research, robotic surgery, and joint replacement in active, high demand patients. Dr. Urish has a financial interest in Peptilogics.

Roshawn Blunt has more than 25 years of experience in the biopharmaceutical and medical device industries. She is the president of Corsaire Corporation, a pharmaceutical commercialization organization. Prior to that, Ms. Blunt founded and was the managing director of 1798, LLC, and has held variety of strategic reimbursement and commercialization positions at The Boston Consulting Group, Amgen, Inc. and Biosense Webster, Inc., a Johnson & Johnson company. Furthermore, Ms. Blunt was vice president of strategy, planning, and communication at Long Beach Memorial Center and Miller Children’s Hospital.

Robin R. Young is the founder and CEO of RRY Publications LLC and PearlDiver Technologies Inc. After a successful 25-year career on Wall Street, Robin has built a multi-channel publishing platform, including Orthopedics this week, which serves more than 300,000 orthopedic surgeons, affiliated healthcare professionals, industry executives and others.

Periprosthetic Joint Infection (PJI)

Joint replacement is the most common major operative procedure with seven million hip and knee replacements anticipated globally in 2030. PJI is the most burdensome adverse event of joint replacement, both medically and economically, making this a major challenge for patients, hospitals and payers.

About Peptilogics

Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation. For more information about Peptilogics, visit www.peptilogics.com or follow the company on Twitter and LinkedIn.

Contact:
Jodie Gillon
SVP Corporate Affairs & Patient Advocacy
Jodie.Gillon@peptilogics.com